Patent intelligence · US
US 11891420
Molecules for organelle-specific protein delivery
Molecules for organelle-specific protein delivery
Patent details — US 11891420
- Jurisdiction
- US
- Status
- granted
- Grant date
- Feb 6, 2024
- Expiration
- Feb 1, 2044
- Applicant
- Larimar Therapeutics, Inc.
- Claims
- 26
- CPC classes
- A61K, A61K38/00, A61K47/64, A61P
Quick answer
US 11891420 (Molecules for organelle-specific protein delivery) is held by Larimar Therapeutics, Inc.. Status: granted. Granted Feb 6, 2024. Expires Feb 1, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Larimar Therapeutics, Inc.
- Grant date
- Expiration
- Claims
- 26
- CPC classes
- A61K, A61K38/00, A61K47/64, A61P, A61P25/16, A61P25/28
More from Larimar Therapeutics, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12390509
Pharmaceutical composition comprising frataxin fusion protein and methods of use thereof
granted -
US 12351611
Molecules for organelle-specific protein delivery
granted -
US 12091437
Molecules for organelle-specific protein delivery
granted -
US 11976100
Methods for treating myelin associated diseases and mitochondria associated diseases
granted
Frequently asked questions
What is US patent 11891420?
US 11891420 (Molecules for organelle-specific protein delivery) is held by Larimar Therapeutics, Inc.. Status: granted. Granted Feb 6, 2024. Expires Feb 1, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11891420?
Larimar Therapeutics, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 5 pharmaceutical patents for this assignee.
When does US 11891420 expire?
Our index shows an expiration date of Feb 1, 2044 (18 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.